Aardvark Therapeutics, Inc. (AARD) earnings
AARD earnings moved a median of -6.93% by the close. Quarterly and annual AARD reports and results, each read against the price at its own news timestamp. Back to the AARD overview →
12 measured AARD earnings events.
Where these AARD earnings landedvs 12 measured AARD earnings reactions
| Middle 50% of AARD earnings reactions | -13.84% to +3.49% |
|---|---|
| Median reaction (to close) | -6.93% |
| Measured reactions | 12 |
Point-in-time · zero look-ahead
Half of the 12 AARD earnings events with a measured close landed between -13.84% and +3.49%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates | Press release | +3.17% | -15.82% | |
| Form 10-Q Aardvark Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +3.17% | -15.82% | |
| Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | -2.10% | -8.11% | |
| Form 10-Q Aardvark Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.10% | -8.11% | |
| Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | -5.83% | -2.78% | |
| Form 10-Q Aardvark Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | +3.24% | |
| Form 10-K Aardvark Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -3.25% | -5.75% | |
| Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates | Press release | +0.00% | +4.26% | |
| Form 10-Q Aardvark Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +4.26% | |
| Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights | Press release | +0.00% | -13.84% | |
| Form 10-Q Aardvark Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -13.84% | |
| Form 10-K Aardvark Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | +10.53% |
Keep exploring
More AARD: analyst actions → · SEC filings → · AARD overview →